Stoic Venture Capital commits further to healthcare following Cardihab success

March 26, 2021 2 min read

Stoic Venture Capital commits further to healthcare following Cardihab success

Stoic Venture Capital has committed to further bulking up its healthcare investments as the prevalence of chronic disease such as cardiovascular disease continues to rise.

 

Stoic Venture Capital Managing Partner Geoff Waring said Stoic was committed to increasing its healthcare and life science holdings while most other venture capital firms focused predominantly on software.

 

Stoic Venture Capital has 9 healthcare companies in its portfolio of 17 companies since establishing three years ago.

 

“Many investors prefer software to health and science-based technology, but in doing so they neglect lucrative opportunities to invest where Australia has a global competitive advantage in its medical research,” Dr Waring said.

 

Cardihab is a virtual program that patients complete remotely while under clinical supervision by qualified healthcare professionals. Supported by weekly phone or video consultations from their clinician, patients can benefit from the convenience of technology enabled care from their home.

 

“Cardihab is targeted at the world’s biggest killer – heart disease. The global cardiac rehab health market size is expected to be worth US$2.5B by 2025.”

 

Dr Waring said Stoic’s unique partnership with university-focused investment fund Uniseed gave investors access to the most promising health and science opportunities such as Cardihab, which was developed at the CSIRO.

 

Cardihab is a landmark Australian digital health platform that facilitates the virtual delivery of cardiac rehabilitation services for patients recovering from cardiac events and living with heart disease.

 

Cardihab has just announced a state-wide agreement with the Tasmanian Department of Health and Royal Flying Doctor Service Tasmania to provide digital cardiac rehabilitation services in public hospitals across the state.

 

“Cardihab provides a solution for patients living in regional and rural areas and will become increasingly important as our health care system strives to meet the needs of our ageing population,” Dr Waring said.

 

Cardihab Chief Executive Officer Helen Souris said Cardihab’s clinically validated platform provided an important solution to managing heart disease

 

About Stoic Venture Capital

Stoic Venture Capital provides financing for early-stage companies, particularly those arising from university research. We are unconditionally registered as an Early Stage Venture Capital Limited Partnership (ESVCLP). We take a collaborative approach to investing in the highest potential companies.

 

https://www.miragenews.com/stoic-venture-capital-commits-further-to-534810/

 



Also in News

Workzone West leads the way in WA
Workzone West leads the way in WA

March 03, 2022 2 min read

THE Workzone West building at 202 Pier Street in the Perth CBD is now the first carbon neutral 6 Star NABERS Energy rated commercial building in Western Australia.
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

February 24, 2022 3 min read

INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals with COPD
Perennial, Arbel double down on SME lender Lumi
Perennial, Arbel double down on SME lender Lumi

February 21, 2022 2 min read

Only two months since it closed a $20 million round, SME lender Lumi has raised another $10 million, thanks to the growth of its loan book drastically exceeding its forecasts.